China Meheco's Unit Gets Nod for Supplementary Application for Lincomycin Hydrochloride Injection After Passing Evaluation

(MT Newswires) -- China Meheco Group's (SHA:600056) unit, Tianfang Pharmaceutical, received approval from the Chinese drug administrator for its drug supplementary application for lincomycin hydrochloride injection after the drug passed regulatory evaluation, according to a Shanghai bourse filing on Wednesday. The drug, which is mainly used for the treatment of severe infections caused by susceptible strains such as streptococci, pneumococci, and staphylococci, was tested for its consistency in quality and efficiency. The Chinese drugmaker's shares dropped less than 2% during the afternoon trade.